Kala Pharmaceuticals – CRL for KPI-121 0.25% poses a Setback for the Company
Kala Pharmaceuticals (NASDAQ: KALA) received a Complete Response Letter (CRL) from the FDA, asking for efficacy data from an additional trial, in response...
Kala Pharmaceuticals (NASDAQ: KALA) received a Complete Response Letter (CRL) from the FDA, asking for efficacy data from an additional trial, in response...
Seelos Therapeutics (NASDAQ: SEEL), a clinical-stage biotechnology Company, announced the acceptance of its Investigation New Drug (IND) application for SLS-005 (trehalose) by the...
Sarepta Therapeutics (NASDAQ: SRPT) faced a setback recently with the FDA rejecting Vyondys 53 (Golodirsen), an experimental drug for Duchenne muscular dystrophy, which...
Niemann–Pick is a rare autosomal recessive inherited disease that is characterized by excessive accumulation of cholesterol and lipids in cells, leading to apoptosis...
Vuzix Corporation, (NASDAQ: VUZI) a Smart-Glasses and Augmented Reality (AR) Technology Company, which was awarded the Consumer Electronics Show (or CES) awards for...
PAVmed, a multiproduct medical device company that is developing solutions for areas with large unmet medical needs, today announced the grant of a...
The Global legal marijuana market is likely to reach over USD 66.3 billion by the end of 2025, as per a report by...
Chronic Pain is the leading cause for seeking medical aid in the U.S. A study undertaken by the Centres for disease control and...
The Global legal marijuana market is likely to reach over USD 66.3 billion by the end of 2025, as per a report by...